IDH2 and cholangiocarcinoma: Recently, the TOPAZ-1 trial established a new standard of care based on chemotherapy and immunotherapy with Durvalumab for patients with advanced biliary tract cancers [117,118]; mounting evidence is now supporting the study of IDH inhibitors in association with immunotherapy for cholangiocarcinoma.